Change to Financial Calendar for 2023 and update regarding class action lawsuit in United States
Apr 17, 2023
Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), announces that publication of its financial results for the full year ending December 31, 2022, previously expected April 19, 2023, are now expected to be published on April 25, 2023. Additional time is required to conclude the presentation of the financial statements. The updated financial calendar for 2023 is available on the Company’s website.
Read moreOrphazyme reports financial results in Interim Report First Half 2022
Sep 26, 2022
Orphazyme A/S (ORPHA.CO) (the “Company”) today announces its Interim Report First Half 2021 for the period January 1 – June 30, 2022.
Orphazyme reports financial results in Interim Report First Half 2022
Orphazyme Interim Report H1 2022
Read moreAdjusted financial outlook for 2022
Sep 25, 2022
Orphazyme A/S (ORPHA.CO) (the “Company”) has decided to adjust its outlook for 2022, as published on June 7, 2022.
Adjusted financial outlook for 2022
Read moreUpdated financial calendar for 2022
Sep 19, 2022
Orphazyme A/S (ORPHA.CO) (the “Company”) announces an update to the Company’s financial calendar in regard to the publication of the Company’s Interim Report First Half 2022.
Updated Financial Calendar for 2022 H1 update
Read moreResolutions passed at the Annual General Meeting
Jun 29, 2022
Orphazyme A/S (ORPHA.CO) (the “Company”), today held its Annual General Meeting, at which the Annual General Meeting.
Resolutions passed at the Annual General Meeting
Read moreUpdated notice to holders of ADSs regarding termination of Deposit Agreement
Jun 20, 2022
Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), hereby provides notice to holders of American Depositary Shares (“ADSs”) evidenced by American Depositary Receipts (“ADRs”) representing deposited common shares of the Company regarding termination of the Deposit Agreement (the “Deposit Agreement”) dated September 28, 2020 among the Company, The Bank of New York Mellon, as depositary (the “the Depositary”), and Owners and ADR Holders (“ADR Holders”).
Updated notice to holders of ADSs regarding termination of Deposit Agreement
Read moreCorrection: Orphazyme Announces Publication of 2021 Financial Results and Annual Report
Jun 8, 2022
Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), today reports its financial results for the period from January 1, 2021, to December 31, 2021, and publishes its Annual Report.
Correction Orphazyme Announces Publication of 2021 Financial Results and Annual Report
Read moreNotice to convene Annual General Meeting
Jun 7, 2022
Orphazyme A/S (ORPHA.CO) (the “Company”), today announces the notice to convene the Company’s Annual General Meeting to be held on.
Appendix 1 Candidates for the Board of Directors 1
Notice to convene Annual General Meeting
Orphazyme Notice to convene AGM 2022
Read moreOrphazyme Announces Publication of 2021 Financial Results and Annual Report
Jun 7, 2022
Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), today reports its financial results for the period from January 1, 2021, to December 31, 2021, and publishes its Annual Report.
Orphazyme Announces Publication of 2021 Financial Results and Annual Report
Read moreOrphazyme completes sale of substantially all of its assets and business activities to KemPharm
May 31, 2022
With reference to company announcement no. 24/2022 dated May 15, 2022, regarding the signing of an agreement to sell substantially all of the Orphazyme’s assets and business activities to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm Inc. (KMPH: NASDAQ, NY), (“KemPharm”), and company announcement no. 28/2022 dated May 30, 2022, regarding the approval of the restructuring proposal, Orphazyme A/S (ORPH) (“Orphazyme” or the “Company”), today announces that it has completed the sale of substantially all of its assets and business activities for a cash consideration of USD 12.8 million and assumption of liabilities estimated to equal approximately USD 5.2 million (the “Sale of Assets”) to KemPharm following the adoption of the restructuring proposal.
Orphazyme completes sale of substantially all of its assets and business activities to KemPharm
Read more